These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8445945)

  • 41. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
    Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular drug resistance in childhood leukemia.
    Veerman AJ; Kaspers GJ; Pieters R
    Ann Hematol; 1994; 69 Suppl 1():S31-4. PubMed ID: 8061109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
    Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
    Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of glufosfamide in childhood acute leukemia.
    Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
    Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
    Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
    Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
    Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.
    Gudowius S; Recker K; Laws HJ; Dirksen U; Tröger A; Wieczorek U; Furlan S; Göbel U; Hanenberg H
    Klin Padiatr; 2006; 218(6):327-33. PubMed ID: 17080335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.
    Holleman A; den Boer ML; Kazemier KM; Janka-Schaub GE; Pieters R
    Blood; 2003 Dec; 102(13):4541-6. PubMed ID: 12920041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
    Czuczman MS; Dodge RK; Stewart CC; Frankel SR; Davey FR; Powell BL; Szatrowski TP; Schiffer CA; Larson RA; Bloomfield CD
    Blood; 1999 Jun; 93(11):3931-9. PubMed ID: 10339502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
    Lugthart S; Cheok MH; den Boer ML; Yang W; Holleman A; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
    Cancer Cell; 2005 Apr; 7(4):375-86. PubMed ID: 15837626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
    Shman TV; Belevtsev MV; Buglova SE
    Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.